Oncimmune Holdings PLC (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced the appointment of Dr. Annalisa Jenkins, MBBS, FRCP to the Company’s Board
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, today announced that it has signed a framework agreement for an exclusive
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that the Company has validated its EarlyCDT®-Liver test on schedule
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology today announced it has appointed Bryan, Garnier & Co. and Berenberg as Joint
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, today announced it has signed an exclusive agreement for distribution of its
In a manuscript published in the journal CHEST, a group of experts discuss recent evidence concerning the benefit, harms, and implementation of low-radiation dose chest computed tomography (CT) in lung cancer screening. The
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced its full year results for the year ended 31 May 2017.
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced it has signed an exclusive agreement for distribution of its EarlyCDT®-Lung
If you are at a high risk for lung cancer, experts recommend that you get screened yearly. But only a very small number of cancers are found through screening, and
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, will be announcing its full year results for the year ended 31
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
